// App-Quantinova.ai

P050 : Effect of Ocrelizumab on Severe Progression of Upper Extremity Impairment in Patients with Primary Progressive Multiple Sclerosis in ORATORIO

Researchers

Presenter

  • Bruno Musch

Principal Investigators

  • Edward J Fox

  • Clyde Markowitz

  • Angela Applebee

  • Xavier Montalban

  • Jerry S Wolinsky

  • Shibeshih Belachew

  • Damian Fiore

  • Ms. Jinglan Pei

  • Gavin Giovannoni

Medical Centers

  • Central Texas Neurology Consultants, Round Rock, TX

  • Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

  • St. Peter’s Health Partners, Albany, NY

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • McGovern Medical School, Houston, TX

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Genentech, Inc., South San Francisico, CA

  • Queen Mary University of London, London, United Kingdom

Locations

  • United States

  • Spain

  • Switzerland

  • United Kingdom

Companies

  • F. Hoffmann-La Roche

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Dermatology

  • Genetic Disorder

Disease

  • Multiple Sclerosis

  • Ectodermal dysplasia-syndactyly syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Ocrelizumab

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved